Updates

** Shares of Australia's Telix Pharmaceuticals TLX.AX fall as much as 5.1% to A$10.9, their lowest level since Jan. 8

** Stock logs its biggest intraday pct loss since Dec. 17

** Citi says TLX's fourth-quarter results did not provide any major numerical surprises

** TLX, after market hours on Tuesday, reported revenue of $208 million, up 46% year-on-year

** Citi says revenue in line with Visible Alpha and its estimates

** Brokerage says investors would likely shrug off results and instead focus on short-term milestone events for co's products

** Earlier this week, TLX said China's NMPA accepted its New Drug Application for prostate imaging cancer product

** Citi analysts, however, do not see the news as a major driver for stock

** Citi keeps "buy/high risk" rating for TLX, target price of A$34 apiece

** All 13 analysts covering the stock rate it "buy" or higher; their median PT is A$24.75 – LSEG data

** Stock lost nearly 55% in 2025

(Reporting by Rajasik Mukherjee in Bengaluru)

((Rajasik.Mukherjee@thomsonreuters.com))